AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05722561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).
Description: Participants are to use the electronic cigarette freely as replacement for smoking combustible cigarettes.
Study NCT04797806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle.
Study NCT04797806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
Study NCT04797806 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Icotinib
Description: Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
Study NCT05614648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine Micropellets
Description: 0.975 mg clonidine hydrochloride as 3 micropellets administered in one injection
Study NCT05614648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tuohy epidural needle
Description: 18-gauge Tuohy epidural needle using a custom-built injector
Study NCT05614648 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tuohy epidural needle
Description: 18-gauge Tuohy epidural needle using a custom-built injector
Study NCT05116306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with hyaluronic acid gel
Study NCT05922241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Costophrenic assisted cough
Description: Therapist places the hands on the costophrenic angles of the patient's rib cage. During the patient's inspiration, the therapist applies a series of three repeated quick-stretch contractions down and in to encourage maximal inspiration. At the end of expiration, the therapist applies a quick stretch down and in on the patient's lower chest to facilitate a stronger diaphragmatic and intercostal muscle contraction. While instructing the patient to cough, the therapist applies strong pressure through the hands in toward the central tendon of the patient's diaphragm
Study NCT05922241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anterior chest compression
Description: The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process
Study NCT05273541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coronavirus vaccination
Description: Patients in this trial need to accept a prime-boost vaccination against SARS-CoV-2 after 6 to 8 months of the first vaccination
Study NCT06507527 — intervention group
Intervention type: OTHER
Intervention: Collection of variables
Description: This is an observational study, so no interventions that are not routine clinical practice are performed. It is only about collecting information on variables that are already collected in normal clinical practice.
Study NCT06181370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGMB-447
Description: AGMB-447 inhaled drug
Study NCT06181370 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo inhaled drug
Study NCT05079477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to sugar-sweetened beverage warning labels
Description: Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
Study NCT05079477 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to calorie information
Description: Calories for all beverages and foods
Study NCT05079477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to calorie information
Description: Calories for all beverages and foods
Study NCT06256991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer 8400 MG [Veltassa]
Description: Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.
Study NCT06256991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.
Study NCT05406609 — intervention group
Intervention type: OTHER
Intervention: Cost
Description: Costs of operating room, drugs and equipments which are used by anesthesia
Study NCT05406609 — intervention group
Intervention type: OTHER
Intervention: Time
Description: Time of using operating room
Study NCT05116306 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propylene glycol
Description: lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with Propylene glycol gel
Study NCT05220813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: local infiltration by lidocaine in the surgical site
Study NCT05220813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: 44patients will receive bupivacaine in ilioinguinal \& iliohypogastric nerve blocks
Study NCT06030739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
Study NCT04912089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGENT
Description: COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
Study NCT06357585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web based education
Description: Web-based training will be provided to the parents in the experimental group regarding care practices for children diagnosed with leukemia.
Study NCT06357585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inactive group
Description: Parents in the control group will continue to receive routine care and treatment.
Study NCT06231680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity
Study NCT04758923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy
Description: Under General anaesthesia cholecystectomy and CBD exploration
Study NCT05010447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Coach App
Description: The avatar-guided app aims to deepen the user's understanding of Acceptance and Commitment Therapy (ACT) and promote application of ACT skills in every-day-life. Event-Sampling-Methodology (ESM) is used to capture the user's progress as it unfolds.
Study NCT05611502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TMS will be administered in a pattern that is either excitatory or inhibitory.
Study NCT05611502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: TMS will be administered in a pattern that is either excitatory or inhibitory.
Study NCT06520007 — intervention group
Intervention type: DRUG
Intervention: Doxycyclin
Description: The drug has been prescribed, as in normal clinical practice, with the National Healthcare System. Patients have been fully informed about interactions, toxicity and posology schedule.
Study NCT05476523 — intervention group
Intervention type: OTHER
Intervention: NeuraLight
Description: NeuraLight is an investigational software-based platform used for measuring eye movements in response to visual stimuli and captured using a simple webcam
Study NCT06203587 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347
Description: The dose of \[68Ga\]Ga-NOTA-WWH347 or \[18F\]F-H3RESCA-WWH347, calculated from the patient's body weight, was 1.8-3.7 MBq \[0.05-0.1 mCi\]/kg, and was administered as an intravenous push, with a single dose given once.
Study NCT04662372 — intervention group
Intervention type: OTHER
Intervention: Description
Description: description of the cognitive and behavioral profile of stroke mimics patients, without evidence of neurological disease.
Study NCT05933590 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cervical Joint Repositioning Error Assessment
Description: The cervical joint repositioning error assessment is a non-invasive diagnostic test used to measure the ability of an individual to accurately reproduce a specific head position in different orientations (flexion, neutral position, 50% range of motion of left rotation, and 50% range of motion of right rotation). Participants in both the chronic migraine group and the control group will undergo this assessment using a digital inclinometer. The primary outcome of this study is the difference between the initial and repositioned cervical joint angles, measured in degrees.
Study NCT06231680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide 50mg
Description: Thalidomide 50mg，po qd；
Study NCT06231680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide 100mg
Description: Thalidomide 100mg，po qd；
Study NCT06231680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide 200mg
Description: Thalidomide 200mg，po qd；
Study NCT06231680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Platinum-based chemotherapy:~1. Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;~2. Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD;~3. Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.
Study NCT06470633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab 1200mg iv q3w
Study NCT06470633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasoun（HIFU）
Description: HIFU treatment at lesion site
Study NCT06470633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2 iv q3w
Study NCT06470633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90mg/m2 iv q3w
Study NCT06470633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 iv q3w
Study NCT04772651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary coaching
Description: dietary coaching
Study NCT05178706 — intervention group
Intervention type: OTHER
Intervention: upper extremity rehabilitation program
Description: Patients with FSHD who have undergone and have not undergone surgery will be given activity training by the same physiotherapist after they agree to participate in the study. Both groups will be given the same exercises, the same number of repetitions and the same frequency. A two-phase exercise protocol will be established and progression will be performed after 4 weeks. The exercises will be based on the upper extremity and will include various types of exercises and the primary affected November muscles in the upper extremity. It is planned that the exercises will be accompanied by a physiotherapist 2 days a week, with a total of 16 sessions for 8 weeks. It is planned that there will be a total of 8-10 exercises in 10 repetitions in the exercise program. The total length of the exercise session will be 30 minutes. It is planned that the same physiotherapist will be one-on-one with the patient from the beginning to the end of the exercises.
Study NCT05178706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Results of assessment
Description: The total follow-up period of participants included in intervention programs will be 8 weeks. Evaluations will be evaluated by physiotherapist before and at the end of treatment.
Study NCT05051072 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia
Description: Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia
Study NCT06080087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-TEAM
Description: I-TEAM is a web-based implementation toolkit that supports to enhance cultural responsiveness of EI providers in their EBP delivery with minoritized families of young autistic children
Study NCT04772651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation on depression
Description: Psychoeducation on depression (50minutes once a week for 4 weeks)
Study NCT05798702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: roux -en-y- gastric bypass
Description: Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament, through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy.
Study NCT05798702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: intensive life style modification
Description: Weight loss will be induced using a VLCD (800-850 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fiber) with replacement meals for 2 months, followed by structured food reintroduction every 2-8 weeks (about 50% carbohydrate, 35% total fat, and 15% protein), and an ongoing structured program with follow-up visits up to 25% body weight loss
Study NCT05465785 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant COVID-19 vaccine (Sf9 cell)
Description: This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
Study NCT05465785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (Sf9 cell)
Description: This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
Study NCT05143294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conectar Jugando Classroom Program
Description: Modern Board Games Intervention in Elementary Classrooms
Study NCT06275841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vepdegestrant
Description: experimental
Study NCT06275841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Experimental treatment to assess an endpoint
Study NCT05185973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: For Baby supplements provided as powder
Description: One sachet daily
Study NCT05185973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Micronutrient powder provided as powder
Description: One sachet daily
Study NCT06249906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercial bone implant product Group
Description: Commercial bone implant product Group with a smooth surface （without particular microstructures）.
Study NCT06249906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirco-structured Bioceramic Group
Description: β-tri-Calcium phosphate with microstructures such as grooves, patterns and so on.
Study NCT05207163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuing medical education
Description: Education section about knowledge of transmissions, severity of viral hepatitis B-C and update treatment strategy of the HBV-HCV
Study NCT06550544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Office hysteroscopy
Description: A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. Vaginoscopic approach will be used. A 5 F grasper will be used to grasp and extract the IUD.~Pain intensity will be assessed by visual analogue scale immediately after the procedure.
Study NCT06550544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided
Description: An alligator forceps will be introduced into the uterine cavity under ultrasound sound guidance. The IUD will be grasped and extracted outside the uterus.~Pain intensity will be assessed by visual analogue scale immediately after the procedure.
Study NCT05632783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin Sulfate Sodium
Description: Chondroitin sulfate 800 mg tablets
Study NCT05632783 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT06583291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic dopaminergic neural precursor cell(iDAP)
Description: Bilateral implantation
Study NCT04709185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 MG Oral Tablet
Description: oral 1 mg dexamethasone at 23:00-24:00 the night before AVS
Study NCT04709185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo at 23:00-24:00 the night before AVS
Study NCT06252454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Description: Furosemide will be used to block C fibers in the lungs, thus lowering intensity of sensation of dyspnea.
Study NCT06252454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodropropizine
Description: Levodropropizine will be used to block C fibers in the airways, to evaluate if this double block of C fibers will have any effect on lowering intensity of dyspnea sensation
Study NCT06252454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodropropizine
Description: Levodropropizine will be used to block C fibers in the airways, to evaluate if this double block of C fibers will have any effect on lowering intensity of dyspnea sensation
Study NCT06252454 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - saline
Description: Placebo will be used as a comparator
Study NCT05389202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perfusion CT scanning
Description: Abdominopelvic CT scan with perfusion and spectral analysis performed 7 days (± 5 days) before prostate embolization.
Study NCT06432361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource Allocation
Description: Those in the intervention condition will receive weekly personalized information summarizing the previous week's resource allocation (e.g., personalized information on how they spent their time and money) in relation to their personal goals, interests, and alcohol use. They will also see a summary of how they spent their time and money in relation to their set goals for the week The information in the intervention feedback will be obtained from participant's responses to the daily surveys on how they spent their time and money each day. Reviewing the intervention feedback should take no longer than 10 minutes.
Study NCT06432361 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessment only control
Description: participants will complete a 3 week monitoring period of daily surveys assessing time spent in various domains during the time, alcohol use, personal goals, and money spent on alcohol and substance-free activities. Each daily survey should take no longer than 5 minutes to complete.
Study NCT06551337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU.
Study NCT05461326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quad tendon
Description: quadriceps tendon autograft
Study NCT05881213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-378 (low-dose)
Description: Quaque day (QD), PO
Study NCT01302106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine plus low dose Ara-C
Description: Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.